Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors

Philip Went, Stephan Dirnhofer, Tiziana Salvisberg, Mahul Amin, So D. Lim, Pierre André Diener, Holger Moch

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

EpCam is an epithelial adhesion molecule expressed in a broad range of carcinomas. Clinical trials with specific humanized anti-EpCam antibodies have shown promising results and have been inaugurated in renal cell carcinoma (RCC) therapy. To study the EpCam expression profile, primary renal cell neoplasms as well as corresponding metastases were evaluated by immunohistochemistry in tissue microarrays. EpCam expression in oncocytomas and chromophobe RCCs was determined on conventional large sections. Moderate or strong EpCam expression was found in eighteen percent of clear cell (n = 147), 75% of chromophobe (n = 12), and 55% of papillary RCCs (n = 20), but not in oncocytomas (n = 3). On large sections, 90% of chromophobe RCCs (n = 20) showed a strong and homogeneous positivity, whereas oncocytomas (n = 15) revealed EpCam positivity in single tumor cells or small clusters. Fourteen percent of RCC metastases (n = 97) showed EpCam expression. Patients with EpCam expressing clear cell RCC showed a trend toward a better prognosis in a Cox regression analysis including stage, grade, and necrosis. The data suggest EpCam as a potential therapeutic target in a subset of patients with RCC. In addition, expression patterns of EpCam could become a helpful tool in the discrimination of chromophobe RCC and oncocytoma.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalAmerican Journal of Surgical Pathology
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Kidney
Renal Cell Carcinoma
Neoplasms
Oxyphilic Adenoma
Epithelial Cell Adhesion Molecule
Neoplasm Metastasis
Kidney Neoplasms
Cell- and Tissue-Based Therapy
Necrosis
Immunohistochemistry
Regression Analysis
Clinical Trials
Carcinoma
Antibodies

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. / Went, Philip; Dirnhofer, Stephan; Salvisberg, Tiziana; Amin, Mahul; Lim, So D.; Diener, Pierre André; Moch, Holger.

In: American Journal of Surgical Pathology, Vol. 29, No. 1, 01.01.2005, p. 83-88.

Research output: Contribution to journalArticle

Went, Philip ; Dirnhofer, Stephan ; Salvisberg, Tiziana ; Amin, Mahul ; Lim, So D. ; Diener, Pierre André ; Moch, Holger. / Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. In: American Journal of Surgical Pathology. 2005 ; Vol. 29, No. 1. pp. 83-88.
@article{6772853a37c04a1bbb266e95e7d4b162,
title = "Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors",
abstract = "EpCam is an epithelial adhesion molecule expressed in a broad range of carcinomas. Clinical trials with specific humanized anti-EpCam antibodies have shown promising results and have been inaugurated in renal cell carcinoma (RCC) therapy. To study the EpCam expression profile, primary renal cell neoplasms as well as corresponding metastases were evaluated by immunohistochemistry in tissue microarrays. EpCam expression in oncocytomas and chromophobe RCCs was determined on conventional large sections. Moderate or strong EpCam expression was found in eighteen percent of clear cell (n = 147), 75{\%} of chromophobe (n = 12), and 55{\%} of papillary RCCs (n = 20), but not in oncocytomas (n = 3). On large sections, 90{\%} of chromophobe RCCs (n = 20) showed a strong and homogeneous positivity, whereas oncocytomas (n = 15) revealed EpCam positivity in single tumor cells or small clusters. Fourteen percent of RCC metastases (n = 97) showed EpCam expression. Patients with EpCam expressing clear cell RCC showed a trend toward a better prognosis in a Cox regression analysis including stage, grade, and necrosis. The data suggest EpCam as a potential therapeutic target in a subset of patients with RCC. In addition, expression patterns of EpCam could become a helpful tool in the discrimination of chromophobe RCC and oncocytoma.",
author = "Philip Went and Stephan Dirnhofer and Tiziana Salvisberg and Mahul Amin and Lim, {So D.} and Diener, {Pierre Andr{\'e}} and Holger Moch",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.pas.0000.146028.70868.7a",
language = "English (US)",
volume = "29",
pages = "83--88",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors

AU - Went, Philip

AU - Dirnhofer, Stephan

AU - Salvisberg, Tiziana

AU - Amin, Mahul

AU - Lim, So D.

AU - Diener, Pierre André

AU - Moch, Holger

PY - 2005/1/1

Y1 - 2005/1/1

N2 - EpCam is an epithelial adhesion molecule expressed in a broad range of carcinomas. Clinical trials with specific humanized anti-EpCam antibodies have shown promising results and have been inaugurated in renal cell carcinoma (RCC) therapy. To study the EpCam expression profile, primary renal cell neoplasms as well as corresponding metastases were evaluated by immunohistochemistry in tissue microarrays. EpCam expression in oncocytomas and chromophobe RCCs was determined on conventional large sections. Moderate or strong EpCam expression was found in eighteen percent of clear cell (n = 147), 75% of chromophobe (n = 12), and 55% of papillary RCCs (n = 20), but not in oncocytomas (n = 3). On large sections, 90% of chromophobe RCCs (n = 20) showed a strong and homogeneous positivity, whereas oncocytomas (n = 15) revealed EpCam positivity in single tumor cells or small clusters. Fourteen percent of RCC metastases (n = 97) showed EpCam expression. Patients with EpCam expressing clear cell RCC showed a trend toward a better prognosis in a Cox regression analysis including stage, grade, and necrosis. The data suggest EpCam as a potential therapeutic target in a subset of patients with RCC. In addition, expression patterns of EpCam could become a helpful tool in the discrimination of chromophobe RCC and oncocytoma.

AB - EpCam is an epithelial adhesion molecule expressed in a broad range of carcinomas. Clinical trials with specific humanized anti-EpCam antibodies have shown promising results and have been inaugurated in renal cell carcinoma (RCC) therapy. To study the EpCam expression profile, primary renal cell neoplasms as well as corresponding metastases were evaluated by immunohistochemistry in tissue microarrays. EpCam expression in oncocytomas and chromophobe RCCs was determined on conventional large sections. Moderate or strong EpCam expression was found in eighteen percent of clear cell (n = 147), 75% of chromophobe (n = 12), and 55% of papillary RCCs (n = 20), but not in oncocytomas (n = 3). On large sections, 90% of chromophobe RCCs (n = 20) showed a strong and homogeneous positivity, whereas oncocytomas (n = 15) revealed EpCam positivity in single tumor cells or small clusters. Fourteen percent of RCC metastases (n = 97) showed EpCam expression. Patients with EpCam expressing clear cell RCC showed a trend toward a better prognosis in a Cox regression analysis including stage, grade, and necrosis. The data suggest EpCam as a potential therapeutic target in a subset of patients with RCC. In addition, expression patterns of EpCam could become a helpful tool in the discrimination of chromophobe RCC and oncocytoma.

UR - http://www.scopus.com/inward/record.url?scp=11144265666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144265666&partnerID=8YFLogxK

U2 - 10.1097/01.pas.0000.146028.70868.7a

DO - 10.1097/01.pas.0000.146028.70868.7a

M3 - Article

C2 - 15613858

AN - SCOPUS:11144265666

VL - 29

SP - 83

EP - 88

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 1

ER -